출판 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2022년11월
암/종양 프로파일링(Cancer/Tumor Profiling) 시장 : 기술 (이뮤노 분석, NGS, PCR), 암 유형 (유방, 폐, 결장 직장), 바이오 마커 유형 (게놈 바이오 마커, 단백질 바이오 마커), 용도 (바이오 마커 검출, 진단, 예후) – 2027 년까지 세계 예측
Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) – Global Forecast to 2027
| 페이지수 | 295 |
| 도표수 | 343 |
| 구성 | 영문조사보고서 |
| 가격 |
The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.
세계 암/종양 프로파일링 시장은 예측 기간 동안 CAGR 10.6%로 성장하여 2022년 97억 달러에서 2027년까지 160억 달러에 이를 것으로 예상됩니다. 이 시장의 성장은 주로 암 연구에 대한 자금 투자 증가와 프로파일링 기술의 기술 발전에 의해 주도됩니다. 또한 맞춤형 의료에 대한 선호도 증가와 현장 진단에 대한 수요 증가는 예측 기간 동안 시장 참여자에게 상당한 성장 기회를 제공할 것으로 예상됩니다. 한편, 샘플 수집 및 보관과 관련된 기술적 문제는 시장 성장을 어느 정도 제한하는 요인입니다.
Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market
Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.
Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period
Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.
Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period
Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.
Based on applications, the research application segment holds the largest market share during the forecast period
Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.
North America is expected to account for the largest share of the cancer/tumor profiling market in 2021
In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.
Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa–5%
Key players in cancer/tumor profiling the market
The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Research Coverage:
The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
• Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.
목차
1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS & EXCLUSIONS 39
1.2.2 MARKETS COVERED 40
FIGURE 1 CANCER/TUMOR PROFILING MARKET 40
1.2.3 YEARS CONSIDERED 41
1.3 CURRENCY CONSIDERED 41
TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS: 41
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH APPROACH 43
FIGURE 2 RESEARCH DESIGN 43
2.1.1 SECONDARY RESEARCH 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY RESEARCH 45
FIGURE 3 PRIMARY SOURCES 45
2.1.2.1 Key data from primary sources 46
2.1.2.2 Insights from primary experts 47
2.1.2.3 Breakdown of primaries 47
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
2.2 MARKET SIZING & VALIDATION APPROACH 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS 49
FIGURE 7 TOP-DOWN APPROACH 50
FIGURE 8 CAGR PROJECTIONS 51
FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 51
2.3 DATA TRIANGULATION APPROACH 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.4 MARKET SHARE ESTIMATION 54
2.5 STUDY ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
2.7 RISK ASSESSMENT 55
TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET 55
3 EXECUTIVE SUMMARY 56
FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 56
FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION) 57
FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) 58
FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 58
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET 59
4 PREMIUM INSIGHTS 61
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW 61
FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 61
4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021) 62
FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 62
4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022–2027) 64
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 64
4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027) 65
FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
5.2.1 DRIVERS 67
5.2.1.1 Rising incidence of cancer 67
FIGURE 22 GLOBAL CANCER INCIDENCE, 2008–2030 67
5.2.1.2 Increasing use of biomarkers in cancer profiling 67
5.2.1.3 Growing investments in cancer research 68
5.2.1.4 Technological advancements in cancer profiling techniques 69
5.2.2 RESTRAINTS 69
5.2.2.1 High capital investments for biomarker discovery & development 69
TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT 70
5.2.2.2 Technical issues related to sample collection & storage 70
5.2.3 OPPORTUNITIES 71
5.2.3.1 Growing preference for personalized medicine 71
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021 71
5.2.3.2 Rising need for point-of-care diagnostics 72
TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE) 72
5.2.4 CHALLENGES 73
5.2.4.1 Low biomarker discovery-to-approval ratio 73
FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS 73
5.2.4.2 Poor regulatory and reimbursement scenario 74
TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.3 INDUSTRY TRENDS 75
5.3.1 INTEGRATION OF OMICS DATA 76
TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES 76
5.3.2 ADVANCES IN LIQUID BIOPSY 77
5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE 78
TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021) 78
5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES 79
6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY 80
6.1 INTRODUCTION 81
TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 81
TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027(USD MILLION) 82
6.2 IMMUNOASSAYS 82
6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET 82
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018–2021 (USD MILLION) 83
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2027 (USD MILLION) 84
6.3 NEXT-GENERATION SEQUENCING 84
6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET 84
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018–2021 (USD MILLION) 86
TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2027 (USD MILLION) 86
6.4 POLYMERASE CHAIN REACTION 87
6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION TO DRIVE MARKET 87
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2021 (USD MILLION) 88
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2027 (USD MILLION) 89
6.5 IN SITU HYBRIDIZATION 89
6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET 89
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018–2021 (USD MILLION) 90
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2027 (USD MILLION) 91
6.6 MICROARRAYS 91
6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET 91
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018–2021 (USD MILLION) 92
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2027 (USD MILLION) 93
6.7 MASS SPECTROMETRY 93
6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET 93
TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018–2021 (USD MILLION) 94
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2027 (USD MILLION) 95
6.8 OTHER TECHNOLOGIES 95
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2021 (USD MILLION) 96
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 96
7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE 97
7.1 INTRODUCTION 98
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 98
TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 98
7.2 BREAST CANCER 99
7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET 99
TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 99
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 100
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 101
7.3 LUNG CANCER 101
7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET 101
FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012−2030 102
TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 103
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 104
7.4 COLORECTAL CANCER 104
7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET 104
FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018) 105
TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 106
TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 106
7.5 PROSTATE CANCER 107
7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET 107
FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020) 107
TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 108
TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 108
7.6 MELANOMA 109
7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS TO DRIVE MARKET 109
TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 109
TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018–2021 (USD MILLION) 110
TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022–2027 (USD MILLION) 110
7.7 OTHER CANCERS 111
FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020) 111
TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018–2021 (USD MILLION) 112
TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 112
8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE 113
8.1 INTRODUCTION 114
TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 114
TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 114
8.2 GENETIC BIOMARKERS 115
8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES 115
TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 116
TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 116
8.3 PROTEIN BIOMARKERS 117
8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS 117
TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 118
TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 118
8.4 OTHER BIOMARKERS 119
TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 119
TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 120
9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 122
TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022–2027 (USD MILLION) 122
9.2 RESEARCH APPLICATIONS 122
TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 123
TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 123
TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 124
TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 124
9.2.1 BIOMARKER DISCOVERY 125
9.2.1.1 Development of personalized medicine and drug development to support market 125
TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018–2021 (USD MILLION) 125
TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022–2027 (USD MILLION) 126
9.2.2 PERSONALIZED MEDICINE 126
9.2.2.1 Rising funding activities in precision medicine to support market 126
TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018–2021 (USD MILLION) 127
TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2027 (USD MILLION) 128
9.3 CLINICAL APPLICATIONS 128
TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 129
TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 129
TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 130
TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 130
9.3.1 DIAGNOSTICS 131
9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market 131
TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 132
TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 132
9.3.2 PROGNOSTICS 133
9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling 133
TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 133
TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 134
9.3.3 MONITORING & TREATMENT 134
9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market 134
TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018–2021 (USD MILLION) 135
TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022–2027 (USD MILLION) 135
9.3.4 SCREENING 136
9.3.4.1 Screening tests to help high-risk patients ascertain outcomes 136
TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018–2021 (USD MILLION) 136
TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022–2027 (USD MILLION) 137
10 CANCER/TUMOR PROFILING MARKET, BY REGION 138
10.1 INTRODUCTION 139
FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021) 139
TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018–2021 (USD MILLION) 140
TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022–2027 (USD MILLION) 140
10.2 NORTH AMERICA 140
TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020) 141
FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 142
FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT 143
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 143
TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 144
TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 144
TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 145
TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 145
TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 146
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 146
TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 146
TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 147
TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 148
10.2.1 US 148
10.2.1.1 High R&D investments for cancer biomarker research to drive market 148
TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 149
TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 149
TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 150
TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 150
TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 150
TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 151
TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 151
TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 151
TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 152
TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
10.2.2 CANADA 153
10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market 153
TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 154
TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 154
TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 154
TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 155
TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 155
TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 155
TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 156
TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 156
TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 156
TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 157
TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 157
10.3 EUROPE 157
FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 158
TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 159
TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 159
TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 160
TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 160
TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 161
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 161
TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 161
TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 162
TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 162
TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 162
TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 163
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 163
10.3.1 GERMANY 163
10.3.1.1 Favorable government health policies to drive market 163
TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 164
TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 164
TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 165
TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 165
TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 166
TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 166
TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 166
TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 167
TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 168
10.3.2 UK 168
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market 168
TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 169
TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 169
TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 169
TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 170
TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 170
TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 170
TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 171
TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 171
TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 171
TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 172
TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 172
10.3.3 FRANCE 172
10.3.3.1 Growing government investments in genomics & proteomics research to drive market 172
TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 173
TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 173
TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 174
TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 174
TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 175
TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 175
TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 175
TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 176
TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 177
10.3.4 ITALY 177
10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market 177
TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 178
TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 178
TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 179
TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 179
TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 180
TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 180
TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 181
TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 181
TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 181
TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 182
TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 182
10.3.5 SPAIN 182
10.3.5.1 Rising incidence of cancer to drive demand for biomarkers 182
TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 183
TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 183
TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 184
TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 184
TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 185
TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 185
TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 185
TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 186
TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 187
10.3.6 REST OF EUROPE (ROE) 187
TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 188
TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 188
TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 189
TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 189
TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 189
TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 190
TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 190
TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 190
TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 191
TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 191
10.4 ASIA PACIFIC 191
FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 192
FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT 193
TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 194
TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 194
TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 194
TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 195
TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 195
TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 196
TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 196
TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 196
TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022–2027 (USD MILLION) 197
TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 198
10.4.1 JAPAN 198
10.4.1.1 Increasing initiatives to boost genomic research to support market 198
TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 199
TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 199
TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 200
TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 200
TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 201
TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 201
TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 201
TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 202
TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 203
10.4.2 CHINA 203
10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products 203
TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 204
TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 204
TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 204
TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 205
TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 205
TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 205
TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 206
TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 206
TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 206
TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 207
TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 207
10.4.3 INDIA 207
10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market 207
TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 208
TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 208
TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 209
TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 209
TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 210
TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 210
TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 210
TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 211
TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 212
10.4.4 REST OF ASIA PACIFIC (ROAPAC) 212
TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 213
TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 213
TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 214
TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 214
TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 214
TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 215
TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 215
TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 215
TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 216
TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 216
10.5 LATIN AMERICA 216
10.5.1 GROWING RESEARCH ACTIVITIES IN PRECISION ONCOLOGY TO SUPPORT MARKET 216
TABLE 241 LATIN AMERICA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 217
TABLE 242 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 217
TABLE 243 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 218
TABLE 244 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 218
TABLE 245 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 219
TABLE 246 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 219
TABLE 247 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 219
TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 220
TABLE 249 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 220
TABLE 250 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 220
TABLE 251 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 221
10.6 MIDDLE EAST & AFRICA 221
10.6.1 GROWING ESTABLISHMENT OF PHARMA RESEARCH COMPANIES TO DRIVE DEMAND FOR CANCER DIAGNOSTICS 221
TABLE 252 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 222
TABLE 253 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 223
TABLE 254 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 223
TABLE 255 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 224
TABLE 256 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 224
TABLE 257 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 224
TABLE 258 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 225
TABLE 259 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 225
TABLE 260 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 225
TABLE 261 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 226
11 COMPETITIVE LANDSCAPE 227
11.1 OVERVIEW 227
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 227
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 227
11.4 MARKET SHARE ANALYSIS 228
FIGURE 36 NEXT-GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER (2021) 228
FIGURE 37 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER (2021) 229
FIGURE 38 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER (2021) 229
11.5 COMPANY EVALUATION QUADRANT 230
11.5.1 STARS 230
11.5.2 EMERGING LEADERS 230
11.5.3 PERVASIVE PLAYERS 230
11.5.4 PARTICIPANTS 231
FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION QUADRANT (2021) 231
11.6 COMPETITIVE SCENARIO 231
11.6.1 PRODUCT LAUNCHES & APPROVALS 232
TABLE 262 PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–OCTOBER 2022) 232
11.6.2 DEALS 232
TABLE 263 DEALS (JANUARY 2019–OCTOBER 2022) 232
11.6.3 OTHERS 233
TABLE 264 OTHERS (JANUARY 2019–OCTOBER 2022) 233
12 COMPANY PROFILES 234
12.1 KEY PLAYERS 234
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ILLUMINA, INC. 234
TABLE 265 ILLUMINA, INC: BUSINESS OVERVIEW 234
FIGURE 40 ILLUMINA, INC: COMPANY SNAPSHOT (2021) 235
12.1.2 QIAGEN N.V. 240
TABLE 266 QIAGEN N.V.: BUSINESS OVERVIEW 240
FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 241
12.1.3 NEOGENOMICS, INC. 245
TABLE 267 NEOGENOMICS, INC: BUSINESS OVERVIEW 245
FIGURE 42 NEOGENOMICS, INC: COMPANY SNAPSHOT (2021) 246
12.1.4 SYSMEX CORPORATION 249
TABLE 268 SYSMEX CORPORATION: BUSINESS OVERVIEW 249
FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 250
12.1.5 HTG MOLECULAR DIAGNOSTICS, INC. 253
TABLE 269 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW 253
FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021) 254
12.1.6 PREDICTIVE ONCOLOGY, INC. (HELOMICS CORPORATION) 256
TABLE 270 PREDICTIVE ONCOLOGY, INC.: BUSINESS OVERVIEW 256
FIGURE 45 PREDICTIVE ONCOLOGY, INC: COMPANY SNAPSHOT (2021) 256
12.1.7 CARIS LIFE SCIENCES 258
TABLE 271 CLARIS LIFE SCIENCES: BUSINESS OVERVIEW 258
12.1.8 NANOSTRING TECHNOLOGIES, INC. 259
TABLE 272 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW 259
FIGURE 46 NANOSTRING TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021) 260
12.1.9 GUARDANT HEALTH, INC. 263
TABLE 273 GUARDANT HEALTH, INC: BUSINESS OVERVIEW 263
FIGURE 47 GUARDANT HEALTH, INC: COMPANY SNAPSHOT (2021) 264
12.1.10 FOUNDATION MEDICINE, INC. 266
TABLE 274 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW 266
12.1.11 F. HOFFMANN-LA ROCHE LTD 267
TABLE 275 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 267
FIGURE 48 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021) 268
12.1.12 THERMO FISHER SCIENTIFIC INC. 270
TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 270
FIGURE 49 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2021) 271
12.1.13 GENSCRIPT BIOTECH CORPORATION 273
TABLE 277 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW 273
FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) 274
12.1.14 TEMPUS LABS 275
TABLE 278 TEMPUS LABS: BUSINESS OVERVIEW 275
12.1.15 HOLOGIC, INC. 277
TABLE 279 HOLOGIC, INC: BUSINESS OVERVIEW 277
FIGURE 51 HOLOGIC, INC: COMPANY SNAPSHOT (2021) 278
12.1.16 EXACT SCIENCES 279
TABLE 280 EXACT SCIENCES: BUSINESS OVERVIEW 279
FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2021) 280
12.1.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 282
TABLE 281 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 282
FIGURE 53 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021) 283
12.1.18 PERSONALIS, INC. 285
TABLE 282 PERSONALIS, INC: BUSINESS OVERVIEW 285
FIGURE 54 PERSONALIS, INC.: COMPANY SNAPSHOT (2021) 285
12.2 OTHER PLAYERS 287
12.2.1 BOREAL GENOMICS INC. 287
TABLE 283 BOREAL GENOMICS, INC: BUSINESS OVERVIEW 287
12.2.2 STRAND LIFE SCIENCES 288
TABLE 284 STRAND LIFE SCIENCES: BUSINESS OVERVIEW 288
12.2.3 LUCENCE HEALTH, INC. 289
TABLE 285 LUCENCE HEALTH, INC.: BUSINESS OVERVIEW 289
12.2.4 ACT GENOMICS CO., LTD. 291
TABLE 286 ACT GENOMICS CO., LTD.: BUSINESS OVERVIEW 291
12.2.5 IMB DX, INC. 293
TABLE 287 IMB DX, INC.: BUSINESS OVERVIEW 293
12.2.6 PERTHERA 294
TABLE 288 PERTHERA: BUSINESS OVERVIEW 294
12.2.7 AGENDIA 295
TABLE 289 AGENDIA: BUSINESS OVERVIEW 295
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 297
13.1 INSIGHTS FROM INDUSTRY EXPERTS 297
13.2 DISCUSSION GUIDE 298
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303
13.4 CUSTOMIZATION OPTIONS 305
13.5 RELATED REPORTS 305
13.6 AUTHOR DETAILS 306
